Business
Universal Ibogaine Inc. provides update on intent to file Clinical Trial Application with Health Canada and confirms securing of Ibogaine drug supply
(TheNewswire) Calgary, Alberta, September 4, 2025 – TheNewswire - Universal ...
About this update from Universal Ibogaine Inc
[{"type":"text","content":"Universal Ibogaine Inc. provides update on intent to file Clinical Trial Application with Health Canada and confirms securing of Ibogaine drug supply\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Calgary, Alberta, September 4, 2025 –\n \n\n TheNewswire -\n \n\n Universal Ibogaine Inc.\n(TSXV: IBO, in USA: IBOGF, in Germany FSE:JC4)  (“\n \n\n UI\n \n\n ” or the\n“\n \n\n Company\n \n\n )\n \n\n is pleased to announce its intention\nto file, within 90 days, an application to Health Canada to initiate\nclinical trials (the Clinical Trial Application, or “\n \n\n CTA\n \n\n ”) with the aim\nof investigating Ibogaine as a promising treatment for addiction for\nopioid use disorder(s) (the “\n \n\n Trial\n \n\n ”).\n \n\n\n\n In addition, the Company has secured a reliable and\ncompliant supply of pharmaceutical-grade Ibogaine to support the\nplanned clinical trial program. The Company confirms that the drug has\nbeen secured and produced in full compliance with Good Manufacturing\nPractice (“\n \n\n GMP\n \n\n ”) standards, ensuring its quality and safety. This\nsourcing will ensure continuous availability of the investigational\ndrug across all trial sites, complying with regulatory standards and\nquality control measures.\n \n\n\n\n Nick Karos, UI CEO noted “This dual milestone\ndemonstrates our firm commitment to advancing innovative addiction\ntherapies.  We are well-positioned to conduct rigorous, high-quality\nclinical studies focused on patient safety and therapeutic\neffectiveness.”\n \n\n\n\n Further updates on progress of the planned Trial and\nclinical data will be provided by the Company in future disclosures.\n The Company notes that there is no guarantee that the CTA will be\napproved once submitted.\n \n\n\n\n About Universal Ibogaine\nInc.\n \n\n\n\n UI is a life sciences company with a mission to\ntransform addiction treatment using medicalized ibogaine through a\nplanned Canadian clinical trial focused on opioid use disorder, and\nultimately to utilize that treatment protocol globally through planned\nfuture licensing agreements.  UI is concurrently developing a state\nof the art holistic addiction treatment protocol at its Kelburn\nRecovery Centre (locate...